Skip to main content
Top
Published in: Virology Journal 1/2016

Open Access 01-12-2016 | Erratum

Erratum to: Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines

Authors: Lei Yin Emily Ang, Horng Khit Issac Too, Eng Lee Tan, Tak-Kwong Vincent Chow, Lynette Pei-Chi Shek, Elizabeth Huiwen Tham, Sylvie Alonso

Published in: Virology Journal | Issue 1/2016

Login to get access

Excerpt

Upon publication, the authors noticed that in the original version of the article [1], two of the authors’ names, ‘Lynette Pei-Chi Shek’ and ‘Elizabeth Huiwen Tham’ in this article do not appear correctly on our website and therefore on the PubMed citation. …
Literature
Metadata
Title
Erratum to: Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines
Authors
Lei Yin Emily Ang
Horng Khit Issac Too
Eng Lee Tan
Tak-Kwong Vincent Chow
Lynette Pei-Chi Shek
Elizabeth Huiwen Tham
Sylvie Alonso
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2016
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-016-0633-0

Other articles of this Issue 1/2016

Virology Journal 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine